SOURCE: Horizon Pharma

Horizon Pharma

December 05, 2013 16:05 ET

Horizon Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

DEERFIELD, IL--(Marketwired - Dec 5, 2013) - Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that on December 4, 2013 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 80,250 shares of common stock to 14 new employees.

Each stock option has an exercise price per share equal to $6.93, the fair market value on the grant date, and vests over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. Each stock option also has a ten year term and is subject to the terms and conditions of the Company's 2011 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The stock options were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).

About Horizon Pharma

Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing products to primary care, orthopedic surgeons, and rheumatologists. The Company markets DUEXIS, and RAYOS/LODOTRA, and will market VIMOVO, which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire and/or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com.

Contact Information

  • Contact
    Robert J. De Vaere
    Executive Vice President and Chief Financial Officer
    Email Contact